Column Capital Advisors’s Quest Diagnostics DGX Stock Holding History

Column Capital Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$487	Sell	4 -1	-20%	-$133	﹤0.01%	758
2023 Q2	$703	Hold	5	–	–	﹤0.01%	764
2023 Q1	$707	Hold	5	–	–	﹤0.01%	785
2022 Q4	$782	Hold	5	–	–	﹤0.01%	771
2022 Q3	$1K	Hold	5	–	–	﹤0.01%	674
2022 Q2	$1K	Hold	5	–	–	﹤0.01%	674
2022 Q1	$1K	Sell	5 -1	-17%	-$139	﹤0.01%	682
2021 Q4	$1K	Sell	6 -7	-54%	-$1.06K	﹤0.01%	707
2021 Q3	$2K	Hold	13	–	–	﹤0.01%	621
2021 Q2	$2K	Hold	13	–	–	﹤0.01%	622
2021 Q1	$2K	Hold	13	–	–	﹤0.01%	608
2020 Q4	$2K	Sell	13 -323	-96%	-$39.4K	﹤0.01%	596
2020 Q3	$38K	Hold	336	–	–	0.01%	287
2020 Q2	$38K	Hold	336	–	–	0.01%	287
2020 Q1	$27K	Sell	336 -186	-36%	-$19.3K	0.01%	271
2019 Q4	$55K	Buy	+522	New	+$54.4K	0.03%	227

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Column Capital Advisors's DGX Position: Q3 2023 in Review

Column Capital Advisors reduced its Quest Diagnostics (DGX) stake by 20% in Q3 2023, selling an estimated $133 and leaving 4 shares worth $487. The position accounts for ﹤0.01% of the portfolio, ranked #758.

Column Capital Advisors first reported a position in DGX in Q4 2019 and has held it in 16 quarters since. The position peaked at $55K in Q4 2019. 794 funds tracked by Wall St. Rank hold DGX as of Q3 2023.

Column Capital Advisors held 4 shares of Quest Diagnostics worth $487 as of Q3 2023.
Column Capital Advisors sold 1 Quest Diagnostics share in Q3 2023, an estimated $133.
Quest Diagnostics made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #758 holding.
Column Capital Advisors first reported a position in Quest Diagnostics in Q4 2019 and has held it in 16 quarters since.
Column Capital Advisors's Quest Diagnostics position peaked at $55K in Q4 2019.
794 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.